Chimeric antigen receptor (CAR)-T cell immunotherapy is highly effective against B lineage cancers but at the expense of potentially serious toxicity such as cytokine release syndrome (CRS) and neurotoxicity. Recent work provided clinical evidence that allogeneic, cord blood CAR-NK cells induce high rates of non-durable clinical responses without CRS or neurotoxicity.

中文翻译：

---

脐带血 CAR-NK 细胞：良好的初始疗效和毒性，但临床反应的持久性尚不清楚

嵌合抗原受体 (CAR)-T 细胞免疫疗法对 B 系癌症非常有效，但以潜在的严重毒性为代价，例如细胞因子释放综合征 (CRS) 和神经毒性。最近的工作提供了临床证据，表明同种异体脐带血 CAR-NK 细胞可诱导高比率的非持久临床反应，而没有 CRS 或神经毒性。